-+ 0.00%
-+ 0.00%
-+ 0.00%

Polaryx wins FDA fast track designation for PLX-200 in three rare diseases

PUBT·04/21/2026 12:47:37
Listen to the news
Polaryx wins FDA fast track designation for PLX-200 in three rare diseases
  • Polaryx Therapeutics secured FDA Fast Track Designation for PLX-200 across four planned indications in SOTERIA Phase 2 basket trial.
  • Latest designations cover CLN3 disease, Krabbe disease, Sandhoff disease, dated April 21, 2026.
  • FDA granted Fast Track status for CLN2 disease in March 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.